Valeant Pharmaceuticals International (NYSE: VRX) is a global, research-based, specialty pharmaceutical company that discovers, develops, manufactures and markets pharmaceutical products, primarily in the areas of neurology, dermatology and infectious disease. Valeant has made rapid strides under a new management team that laid out a strategic vision with a renewed focus on its specialty pharmaceuticals business, and has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.
Valeant is unique as a specialty pharmaceutical company, with a truly global infrastructure and the ability to discover new molecules, take them through the clinic and fully commercialize them as global products. Valeant is a mid-sized specialty pharmaceutical company with revenues in 2004 of $683 million, which included product sales of $606 million. These sales are generated through 575 products and more than 2,400 stock keeping units, and are sold by approximately 1,000 sales representatives around the world.
Valeant has a world-class research and development organization with four late-stage clinical compounds and numerous discovery targets and a global manufacturing network currently comprised of 12 factories that is actively in the process of being rationalized to five sites worldwide.
Valeant is an international pharmaceutical company building a future focused on growth and innovation, as well as true value creation for its shareholders.
VIRAMIDINE, PRADEFOVIR and RETIGABINE are products in clinical development. None of them have been found to be safe or effective for the treatment of any disease or illness. They may not be sold or promoted in the United States unless and until they are approved by the FDA. Similar restrictions apply in other countries.
